Pre-clinical studies using obese and diabetic mice (e.g., db/db mice and high-fat-diet-induced obese mice), Zucker diabetic fatty rats, HepG2 cells, and primary hepatocytes from human and rodent livers have demonstrated liraglutide’s efficacy in reducing hepatic steatosis and improving insulin sensitivity and liver health markers [211,212,213,214,215]. Here, INS is linked to Hepatic steatosis.